These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 17562846

  • 1. Neutralizing antibodies to interferon.
    Noronha A.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 12; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 3. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul 12; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 5. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 6. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 03; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 7. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

  • 8. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2007 Mar 12; 13(2):208-14. PubMed ID: 17439886
    [Abstract] [Full Text] [Related]

  • 9. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS, Koch-Henriksen N, Bendtzen K.
    Mult Scler; 2007 Jun 12; 13(5):616-21. PubMed ID: 17548440
    [Abstract] [Full Text] [Related]

  • 10. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 12; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 11. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM, Jack CS, Lapierre Y, Arbour N, Bar-Or A, Antel JP.
    Arch Neurol; 2006 Sep 12; 63(9):1296-9. PubMed ID: 16966508
    [Abstract] [Full Text] [Related]

  • 12. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2001 Mar 12; 12(1):56-61. PubMed ID: 11282547
    [Abstract] [Full Text] [Related]

  • 13. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T, Sölberg Sørensen P, Rice G.
    J Neurol; 2004 Jun 12; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [Abstract] [Full Text] [Related]

  • 14. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 15. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M.
    Mult Scler; 2007 Aug 25; 13(7):895-9. PubMed ID: 17468449
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2012 Dec 25; 18(12):1775-81. PubMed ID: 22551640
    [Abstract] [Full Text] [Related]

  • 17. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 18. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA, Giovannoni G.
    Mult Scler; 2007 Jun 10; 13(5):567-77. PubMed ID: 17548434
    [Abstract] [Full Text] [Related]

  • 19. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ.
    J Neurol Sci; 2008 Sep 15; 272(1-2):8-19. PubMed ID: 18620708
    [Abstract] [Full Text] [Related]

  • 20. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS, Rice GP, Alsop JC, PRISMS Study Group.
    Neurology; 2005 Jul 12; 65(1):48-55. PubMed ID: 16009884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.